Logo
x

Search

Subscribe Now

cytokinetics

Cytokinetics Reports the US FDA’s NDA Acceptance of Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Reports the US FDA’s NDA Acceptance of Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy

  • December 3, 2024
Cytokinetics Expands its Funding Collaboration with Royalty Pharma to Commercialize Aficamten and Advance R&D Pipeline

Cytokinetics Expands its Funding Collaboration with Royalty Pharma to Commercialize Aficamten and Advance R&D Pipeline

  • May 23, 2024
Cytokinetics Reports Results from the P-III (SEQUOIA-HCM) Study of Aficamten for Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Reports Results from the P-III (SEQUOIA-HCM) Study of Aficamten for Obstructive Hypertrophic Cardiomyopathy

  • December 28, 2023
Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

  • March 10, 2022
Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyop...

  • February 24, 2022
Cytokinetics Presents Results of Omecamtiv Mecarbil in P-III (METEORIC-HF) Trial for Heart Failure with Reduced Ejection Fraction at ACC 2022

Cytokinetics Presents Results of Omecamtiv Mecarbil in P-III (METEORIC-HF) Trial for Heart Failure with Reduced Ejection Fraction...

  • February 16, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.